Antisense-mediated redirection of mRNA splicing

Cellular and Molecular Life Sciences

Volumn 60, Issue 5, 2003, Pages 825-833

  Vacek, M ^a   Sazani, P ^a,b   Kole, R ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense; Gene therapy; Oligonucleotides; snRNAs; Splicing

Indexed keywords

2' (2 METHYL)OLIGORIBONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; BETA GLOBIN; CALCIUM CHANNEL; COMPLEMENTARY RNA; DNA DIRECTED RNA POLYMERASE III; DYSTROPHIN; INTERLEUKIN 5; MESSENGER RNA PRECURSOR; MYC PROTEIN; OLIGORIBONUCLEOTIDE; PROTEIN BCL X; PROTEOME; RIBONUCLEASE H; RNA POLYMERASE II; SMALL NUCLEAR RNA; TAU PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ACCURACY; ALTERNATIVE RNA SPLICING; ASSAY; ATAXIA TELANGIECTASIA; BETA THALASSEMIA; CELL DIVISION; DISEASE COURSE; EPISOME; EXPRESSION VECTOR; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; GENETIC VARIABILITY; HUMAN; HYPOTHESIS; INTRACELLULAR SPACE; INTRON; MISSENSE MUTATION; NEUROFIBROMATOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PLASMID; PLASTICITY; POINT MUTATION; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; RNA STRUCTURE; RNA TRANSCRIPTION; RNA TRANSLATION; SPLICEOSOME; STOP CODON; TARGET CELL; TRANS SPLICING; UPREGULATION;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0038614842     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-003-3042-7     Document Type: Review

References (84)

1. Brenner R., Yu J. Y., Srinivasan K., Brewer L., Larimer J. L., Wilbur J. L. and Atkinson N. S. (2000) Complementation of physiological and behavioral defects by a slowpoke Ca(2+)-activated K(+) channel transgene. J. Neurochem. 75: 1310-1319
2. Schmucker D., Clemens J. C., Shu H., Worby C. A., Xiao J., Muda M. et al. (2000) Drosophila Dscam is an axon guidance receptor exhibiting extraordinary molecular diversity. Cell 101: 671-684
3. Consortium I. H. G. S. (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921
4. Graveley B. R. (2001) Alternative splicing: increasing diversity in the proteomic world. Trends Genet. 17: 100-107
5. Kan Z., Rouchka E. C., Gish W. R. and States D. J. (2001) Gene structure prediction and alternative splicing analysis using genomically aligned ESTs. Genome Res. 11: 889-900
6. Pertea M., Lin X. and Salzberg S. L. (2001) GeneSplicer: a new computational method for splice site prediction. Nucleic Acids Res. 29: 1185-1190
7. Thanaraj T. A. and Robinson A. J. (2000) Prediction of exact boundaries of exons. Brief Bioinform 1: 343-356
8. Krainer A. (1997) Eukaryotic mRNA Processing, Oxford University Press, New York
9. Zhuang Y. and Weiner A. M. (1990) The conserved dinucleotide AG of the 3′ splice site may be recognized twice during in vitro splicing of mammalian mRNA precursors. Gene 90: 263-269
10. Cartegni L., Chew S. L. and Krainer A. R. (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 3: 285-298
11. Kole R. and Sazani P. (2001) Antisense effects in the cell nucleus: modification of splicing. Curr. Opin. Mol. Ther. 3: 229-234
12. Mercatante D., Sazani P. and Kole R. (2001) Modification of alternatice splicing pathways as a potential chemotherapy for cancer and other diseases. Current Cancer Drug Targets 1: 211-230
13. Krawczak M., Reiss J. and Cooper D. N. (1992) The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes causes and consequences. Hum. Genet. 90: 41-54
14. Teraoka S. N., Telatar M., Becker-Catania S., Liang T., Onengut S., Tolun A. et al. (1999) Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. Am. J. Hum. Genet. 64: 1617-1631
15. Kole R. and Mercatante D (2001) Pre-mRNA splicing as a target for antisense oligonucleotides. In: Antisense Drug Technology: Principles, Strategies and Applications, pp. 517-539, Crooke S. (ed.), Marcel Dekker, New York
16. Mercatante D. R., Bortner C. D., Cidlowski J. A. and Kole R. (2001) Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells, analysis of apoptosis and cell death. J. Biol. Chem. 276: 16411-16417
17. Huisman T. H. (1990) Frequencies of common beta-thalassaemia alleles among different populations: variability in clinical severity. Br. J. Haematol. 75: 454-457
18. Gorman L., Suter D., Emerick V., Schumperli D. and Kole R. (1998) Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc. Natl. Acad. Sci. USA 95: 4929-4934
19. Suter D., Tomasini R., Reber U., Gorman L., Kole R. and Schumperli D. (1999) Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human beta-thalassemic mutations. Hum. Mol. Genet. 8: 2415-2423
20. Gorman L., Mercatante D. R. and Kole R. (2000) Restoration of correct splicing of thalassemic beta-globin pre-mRNA by modified U1 snRNAs. J. Biol. Chem. 275: 35914-35919
21. Vacek M. M., Ma H., Gemignani F., Lacerra G., Kafri T. and Kole R. (2002) High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA. Blood 101: 104-111
22. Sierakowska H., Sambade M. J., Agrawal S. and Kole R. (1996) Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 93: 12840-12844
23. Lacerra G., Sierakowska H., Carestia C., Fucharoen S., Summerton J., Weller D. et al. (2000) Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc. Natl. Acad. Sci. USA 97: 9591-9596
24. Suwanmanee T., Sierakowska H., Lacerra G., Svasti S., Kirby S., Walsh C. E. et al. (2002) Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. Mol. Pharmacol. 62: 545-553
25. Vacek M. M., Ma H., Gemignani F., Lacerra G., Kafri T. and Kole R. (2003) High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA. Blood 101: 104-111
26. Scherr M. and Eder M. (2002) Gene transfer into hematopoietic stem cells using lentiviral vectors. Curr. Gene Ther. 2: 45-55
27. Koenig M., Beggs A. H., Moyer M., Scherpf S., Heindrich K., Bettecken T. et al. (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am. J. Hum. Genet. 45: 498-506
28. De Angelis F. G., Sthandier O., Berarducci B., Toso S., Galluzzi G., Ricci E. et al. (2002) Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. Proc. Natl. Acadi Sci. USA 99: 9456-9461
29. Mansfield S. G., Kole J., Puttaraju M., Yang C. C., Garcia-Blanco M. A. et al. (2000) Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. Gene Ther. 7: 1885-1895
30. Liu X., Jiang Q., Mansfield S. G., Puttaraju M., Zhang Y., Zhou W. et al. (2002) Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat. Biotechnol. 20: 47-52
31. Bertrand E., Castanotto D., Zhou C., Carbonnelle C., Lee N. S., Good P. et al. (1997) The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA 3: 75-88
32. Baserga S. and Steitz J. A (1993) The diverse world of small ribonucleoproteins. In: The RNA World, pp. 359-382, Gesteland R. and Atkins J. F. (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor
33. Grimm C., Stefanovic B. and Schumperli D. (1993) The low abundance of U7 snRNA is partly determined by its Sm binding site. EMBO J. 12: 1229-1238
34. Phillips M. I., Tang Y., Schmidt-Ott K., Qian K. and Kagiyama S. (2002) Vigilant vector: heart-specific promoter in an adeno-associated virus vector for cardioprotection. Hypertension 39: 651-655
35. Kafri T. (2001) Lentivirus vectors: difficulties and hopes before clinical trials. Curr Opin Mol Ther 3: 316-326
36. Breyer B., Jiang W., Cheng H., Zhou L., Paul R., Feng T. et al. (2001) Adenoviral vector-mediated gene transfer for human gene therapy. Curr. Gene Ther. 1: 149-162
37. Amalfitano A. and Parks R. J. (2002) Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr. Gene Ther. 2: 111-133
38. Robbins P. D., Tahara H. and Ghivizzani S. C. (1998) Viral vectors for gene therapy. Trends Biotechnol. 16: 35-40
39. Strayer D., Branco F., Zern M., Yam P., Calarota S., Nichols C. et al. (2002) Durability of transgene expression and vector integration: recombinant SV40-derived gene therapy vectors. Mol. Ther. 6: 227
40. Sprague J. E., Worst T. J., Haynes K., Mosler C. R., Nichols D. E. and Kane M. D. (2001) The pharmacodynamic characterization of an antisense oligonucleotide against monoamine oxidase-B (MAO-B) in rat brain striatal tissue. Cell. Mol. Neurobiol. 21: 53-64
41. Friedman K. J., Kole J., Cohn J. A., Knowles M. R., Silverman L. M. and Kole R. (1999) Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J. Biol. Chem. 274: 36193-36199
42. Karras J. G., McKay R. A., Dean N. M. and Monia B. P. (2000) Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing. Mol. Pharmacol. 58: 380-387
43. Giles R. V., Spiller D. G., Clark R. E. and Tidd D. M. (1999) Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA. Antisense Nucleic Acid Drug Dev. 9: 213-220
44. Kalbfuss B., Mahon S. A. and Misteli T. (2001) Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J. Biol. Chem. 276: 42986-42993
45. Lim S. R. and Hertel K. J. (2001) Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3′ splice site pairing. J. Biol. Chem. 276: 45476-45483
46. Mercatante D., Mohler J. L and Kole R. (2002) Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J. Biol. Chem. 277: 49374-49382
47. Taylor J. K., Zhang Q. Q., Wyatt J. R. and Dean N. M. (1999) Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol. 17: 1097-1100
48. Suwanmanee T., Sierakowska H., Lacerra G., Svasti S., Kirby S., Walsh C. et al. (2002) Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. Mol. Pharmacol. 62: 545-553
49. Lewis J., Yang B., Kim R., Sierakowska H., Kole R., Smithies O. et al. ( 1998) A common human beta globin splicing mutation modeled in mice. Blood 91: 2152-2156
50. Suwanmanee T., Sierakowska H., Fucharoen S. and Kole R. (2002) Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder. Mol. Ther. 6: 718-726
51. Bulfield G., Siller W. G., Wight P. A. and Moore K. J. (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. USA 81: 1189-1192
52. Mann C. J., Honeyman K., Cheng A. J., Ly T., Lloyd F., Fletcher S. et al. (2001) Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl. Acad. Sci. USA 98: 42-47
53. van Deutekom J. C., Bremmer-Bout M., Janson A. A., Ginjaar I. B., Baas F., den Dunnen J. T. et al. (2001) Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum. Mol. Genet. 10: 1547-1554
54. Aartsma-Rus A., Bremmer-Bout M., Janson A., den Dunnen J., van Ommen G., and van Deutekom J. (2002) Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 12: S71
55. Dickson G., Hill V. and Graham I. (2002) Screening for antisense modulation of dystrophin pre-mRNA splicing. Neuromuscul. Disord. 12: S67
56. Micklefield J. (2001) Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. Curr. Med. Chem. 8: 1157-1179
57. Manoharan M. (1999) 2′-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim. Biophys. Acta. 1489: 117-130
58. Dominski Z. and Kole R. (1993) Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 90: 8673-8677
59. Baker B. F., Lot S. S., Condon T. P., Cheng-Flournoy S., Lesnik E. A., Sasmor H. M. et al. (1997) 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272: 11994-12000
60. Lind K. E., Mohan V., Manoharan M. and Ferguson D. M. (1998) Structural characteristics of 2"-O-(2-methoxyethyl)-modified nucleic acids from molecular dynamics simulations. Nucleic Acids Res. 26: 3694-3799
61. Geary R. S., Watanabe T. A., Truong L., Freier S., Lesnik E. A., Sioufi N. B. et al. (2001) Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296: 890-897
62. Yu R. Z., Zhang H., Geary R. S., Graham M., Masarjiau L., Lemonidis K. et al. (2001) Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J. Pharmacol. Exp. Ther. 296: 388-395
63. Zhang H., Cook J., Nickel J., Yu, R. Stecker K., Myers K. et al. (2000) Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. BiotechnoL 18: 862-867
64. Griffey R. H., Monia B. P., Cummins L. L., Freier S., Greig M. J. et al. (1996) 2′-O-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense olignnucleotides. J. Med. Chem. 39: 5100-5109
65. Teplova M., Wallace S. T., Tereshko V., Minasov G., Symons A. M., Cook P. D. et al. (1999) Structural origins of the exonuclease resistance of a zwitterionic RNA. Proc. Natl. Acad. Sci. USA 96: 14240-14245
66. Obika S., Uneda T., Sugimoto T., Nanbu D., Minami T., Doi T. et al. (2001) 2′-O,4′-C-Methylene bridged nucleic acid (2′,4′-BNA): synthesis and triplex-forming properties. Bioorg. Med. Chem. 9: 1001-1011
67. Torigoe H., Hari Y., Sekiguchi M., Obika S. and Imanishi T. (2001) 2′-O,4′-C-methylene bridged nucleic acid modification promotes pyrimidine motif triplex DNA formation at physiological pH. Thermodynamic and kinetic studies. J. Biol. Chem. 276: 2354-2360
68. Renneberg D., Bouliong E., Reber U., Schumperli D. and Leumann C. J. (2002) Antisense properties of tricyclo-DNA. Nucleic Acids Res. 30: 2751-2757.
69. Orum H. and Wengel J. (2001) Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development. Curr. Opin. Molec. Ther. 3: 239-243
70. Summerton J., and Weller D. (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid. Drug Dev. 7: 187-195
71. Summerton J. (1999) Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1489: 141-158
72. Nielsen P. E., Egholm M., Berg R. H. and Buchardt O. (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254: 1497-1500
73. Harvey J. C., Peffer N. J., Bisi J. E., Thomson S. A., Cadilla R., Josey J. A. et al. (1992) Antisense and antigene properties of peptide nucleic acids. Science 258: 1481-1485
74. Miller P. (1998) Oligonucleotide methylphosphonate: synthesis and properties. In: Applied Antisense Oligonucleotide Technology, pp. 3-22, Stein C. and Krieg A. M. (eds.), Wiley-Liss, New York
75. DeDionisio L. and Gryaznov S. M. (1995) Analysis of a ribonuclease H digestion of N3′ → P5′ phosphoramidate-RNA duplexes by capillary gel electrophoresis. J. Chromatogr. B. Biomed. Appl. 669: 125-131
76. Heidenreich O., Gryaznov S. and Nerenberg M. (1997) RNase H-independent antisense activity of oligonucleotide N3′ → P5′ phosphoramidates. Nucleic Acids Res. 25: 776-780
77. Sazani P., Kang S. H., Maier M. A., Wei C., Dillman J., Summerton J. et al. (2001) Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res. 29: 3965-3974
78. Sazani P., Gemignani F., Kang S. H., Maier M. A., Manoharan M., Persmark M. et al. (2002) Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol 20: 1228-1233
79. Gemignani F., Landi S., DeMarini D. M. and Kole R. (2001) Spontaneous and MNNG-induced reversion of an EGFP construct in HeLa cells: an assay for observing mutations in living ceils by fluorescent microscopy Hum. Mutat. 18: 526-534
80. Hertel K. J., Lynch K. W. and Maniatis T. (1997) Common themes in the function of transcription and splicing enhancers. Curr. Opin. Cell Biol. 9: 350-357
81. Blencowe B. J. (2000) Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem. Sci. 25: 106-110
82. Hastings M. L. and Krainer A. R. (2001) Pre-mRNA splicing in the new millennium. Curr. Opin. Cell Biol. 13: 302-309
83. Sierakowska H., Sambade M. J., Schumperli D. and Kole R. (1999) Sensitivity of splice sites to antisense oligonucleotides in vivo. RNA 5: 369-377
84. Berget S. M. (1995) Exon recognition in vertebrate splicing. J. Biol. Chem. 270: 2411-2414